Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014:2014:282196.
doi: 10.1155/2014/282196. Epub 2014 Mar 23.

Intestinal type of lung adenocarcinoma in younger adults

Jelena Stojsic  1 , Milica Kontic  2 , Dragan Subotic  3 , Marko Popovic  4 , Dragana Tomasevic  5 , Jelena Lukic  5
Affiliations

Intestinal type of lung adenocarcinoma in younger adults

Jelena Stojsic et al. Case Rep Pulmonol. 2014.

Abstract

Intestinal type of lung adenocarcinoma (ILADC) was initially described by Tsao and Fraser in 1991. Morphology and immunophenotype of ILADC are the same as in colorectal adenocarcinoma. Rectocolonoscopy must be performed to exclude colorectal origin of adenocarcinoma. Colorectal adenocarcinoma claimed to be genetically similar to an ILADC. Patients. We describe 24- and 26-year-old patients of both genders who went under surgery because of a lung tumor mass detected on CT scan. ILADC was diagnosed on resected lung specimens. According to positivity of Cytokeratin20, CDX-2, and Villin, respectively, and negativity of Cytokeratin7, TTF-1, Napsin-A, SurfactantB, MUC-1, and MUC-2, respectively, ILADC was diagnosed. KRAS mutation was detected in tumor tissue of the male patient. Conclusion. Rectocolonoscopy is the only relevant method for distinguishing the intestinal type of lung adenocarcinoma from metastatic colorectal carcinoma because immunohistochemistry and detection of mutation status are frequently the same in both types of adenocarcinoma. More investigations are needed for further understanding of ILADC in purpose of personalized lung carcinoma therapy particularly introducing detection of mutation status, especially in younger patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tumor shadow was revealed in left lower lobe of the lung on chest CT scan.
Figure 2
Figure 2
Pathological finding of ILADC in female patient: (2a) intestinal type of lung adenocarcinoma, H&Ex10, and its immunohistochemical profile: positivity of (2b) Cytokeratin 20×20; (2c) CDX-2×20; (2d) Villin ×10.
Figure 3
Figure 3
KRAS mutation was detected in male patient.
See this image and copyright information in PMC

References

    1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. World Health Organisation Classification of Tumours. Pathology and Genetics of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
    1. Travis WD, Colby TV, Corrin B, Shimamoto Y, Brambilla E, Sobin LH. World Health Organization International Histological Classification of Tumors. Berlin, Germany: Springer; 1999.
    1. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung carcinoma/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. Journal of Thoracic Oncology. 2011;6(2):244–285. - PMC - PubMed
    1. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009;54(1):12–27. - PubMed
    1. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung carcinoma: relevance for clinical practice and clinical trials. Journal of Clinical Oncology. 2013;31(8):992–1001. - PubMed

LinkOut - more resources